{"id":7066,"date":"2025-05-22T13:40:05","date_gmt":"2025-05-22T10:40:05","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=7066"},"modified":"2025-05-22T13:40:05","modified_gmt":"2025-05-22T10:40:05","slug":"new-drug-combinations-could-cut-heart-failure-deaths-by-60","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/new-drug-combinations-could-cut-heart-failure-deaths-by-60\/","title":{"rendered":"New Drug Combinations Could Cut Heart Failure Deaths by 60%"},"content":{"rendered":"
New Drug Combinations Could Cut Heart Failure Deaths by 60%<\/div>\n
<\/div>\n
Source: Medscape.<\/div>\n
Date: May 15, 2025<\/div>\n
Event: 91st German Society of Cardi0vascular medicine annular conference.<\/div>\n
<\/div>\n
Key Points:<\/div>\n
1. Early and Optimized Treatment Saves Lives<\/span><\/div>\n
\u2022 Starting drug therapy immediately after diagnosis improves outcomes.<\/span><\/div>\n
\u2022 Mortality in heart failure with reduced or mildly reduced ejection fraction (HFrEF or HFmrEF) can drop by up to 60% with optimized drug combinations.<\/span><\/div>\n
2. Recommended Quadruple Drug Combo (ESC Guidelines 2021):<\/span><\/div>\n
\u2022 ACE inhibitor or ARNI (sacubitril\/valsartan)<\/span><\/div>\n
\u2022 Beta-blocker<\/span><\/div>\n
\u2022 Mineralocorticoid receptor antagonist (MRA)<\/span><\/div>\n
\u2022 SGLT2 inhibitor (e.g. dapagliflozin)<\/span><\/div>\n
3. Loop diuretics are added for fluid overload.<\/span><\/div>\n
<\/div>\n
Fast Diagnosis is Critical<\/div>\n
\u2022 Many patients face delays in diagnosis, which leads to worse outcomes.<\/span><\/div>\n
\u2022 In Sweden\u2019s REVOLUTION-HF study, only 29% of patients with high natriuretic peptides were diagnosed within a year.<\/span><\/div>\n
<\/div>\n
Recommended Drug Initiation Sequence:<\/div>\n
1. Start SGLT2 inhibitor \u2192 check tolerance<\/span><\/div>\n
2. Add MRA alongside<\/span><\/div>\n
3. Titrate beta-blocker over 4 weeks<\/span><\/div>\n
4. Start and adjust ARNI over 5 weeks (once blood pressure is stable)<\/span><\/div>\n
<\/div>\n
Life Expectancy Gains from Quadruple Therapy:<\/div>\n
\u2022 55-year-old patients may gain 6.3 years of life compared to older dual therapy.<\/span><\/div>\n
\u2022 Even 80-year-old patients may gain 1.4 years of life.<\/span><\/div>\n
<\/div>\n
Beyond Medications \u2013 Devices and Monitoring Matter Too:<\/div>\n
\u2022 Consider ICDs, CRT devices, and pacemakers for advanced HF.<\/span><\/div>\n
\u2022 Telemonitoring is underused but can save lives.<\/span><\/div>\n
\u2022 Managing arrhythmias (like atrial fibrillation) also improves survival.<\/span><\/div>\n
<\/div>\n
New Medications and Innovations:<\/div>\n
\u2022 Vericiguat: A new oral drug for patients worsening despite optimal therapy. Can be used even with low kidney function (eGFR \u226515).<\/span><\/div>\n
\u2022 Finerenone: A nonsteroidal MRA shown to reduce HF hospitalizations, especially in patients with diabetic kidney disease.<\/span><\/div>\n
<\/div>\n
Iron Deficiency in HF:<\/div>\n
\u2022 IV iron (ferric carboxymaltose) improves symptoms and exercise tolerance.<\/span><\/div>\n
\u2022 Meta-analysis of 6 trials shows 28% reduction in HF hospitalizations + CV death.<\/span><\/div>\n
1-https:\/\/click.mail.medscape.com\/?qs=a31d72e10dd07c91e4ac96e2b3edf576090fbe161849f4805b4aa38e468b04296e75f719e2263d979e689b8cbe0b1b500a01ad405ac3bf782393706ee63f15d1<\/a><\/div>\n
2-https:\/\/academic.oup.com\/eurheartj\/article\/42\/36\/3599\/6358045<\/a><\/div>\n
3-https:\/\/herzmedizin.de\/fuer-aerzte-und-fachpersonal\/kongresse\/dgk-jahrestagung-2025.html<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

New Drug Combinations Could Cut Heart Failure Deaths by 60% Source: Medscape. Date: May 15, 2025 Event: 91st German Society of Cardi0vascular medicine annular conference. Key Points: 1. Early and Optimized Treatment Saves Lives \u2022 Starting drug therapy immediately after diagnosis improves outcomes. \u2022 Mortality in heart failure with reduced or mildly reduced ejection fraction […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7066","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7066","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=7066"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7066\/revisions"}],"predecessor-version":[{"id":7067,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/7066\/revisions\/7067"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=7066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=7066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=7066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}